Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2009

Moscat J, Diaz-Meco MT. To aggregate or not to aggregate? A new role for p62. EMBO Rep. 2009;10(8):804.

Lu DY, Nassar A, Siddiqui MT. High-grade urothelial carcinoma: comparison of SurePath liquid-based processing with cytospin processing. Diagn Cytopathol. 2009;37(1):16-20.

Tsibris AM, Paredes R, Chadburn A, Su Z, Henrich TJ, Krambrink A, et al. Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clin Infect Dis. 2009;48(5):642-9.

2008

Feklistov A, Mekler V, Jiang Q, Westblade LF, Irschik H, Jansen R, et al. Rifamycins do not function by allosteric modulation of binding of Mg2+ to the RNA polymerase active center. Proc Natl Acad Sci U S A. 2008;105(39):14820-5.

Alsharif M, Aslan DL, Jessurun J, H Gulbahce E, Pambuccian SE. Cytologic diagnosis of metastatic seminoma to the prostate and urinary bladder: a case report. Diagn Cytopathol. 2008;36(10):734-8.

Heller KN, Arrey F, Steinherz P, Portlock C, Chadburn A, Kelly K, et al. Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1. Int J Cancer. 2008;123(12):2824-31.

Yoon SO, Jeon YK, Paik JH, Kim WY, Kim YA, Kim JE, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53(2):205-17.

Fiorentino M, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, et al. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest. 2008;88(12):1340-8.

Cellini C, Hoda SA, Spigland N. Lupus-associated vasculitis manifesting as acute appendicitis in a 16 year old girl. Pediatr Rheumatol Online J. 2008;6:10.

Diaz-Meco MT, Moscat J. Akt regulation and lung cancer: a novel role and mechanism of action for the tumor suppressor Par-4. Cell Cycle. 2008;7(18):2817-20.